UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 000-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 13-34446 ...

Regeneron Pharmaceuticals, Inc. (REGN) delivered better-than-expected fourth-quarter 2023 results, despite declining sales of its lead drug, Eylea (aflibercept). Dupixent maintained its stellar performance, driven by continued strong demand in the approved indications, atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis and prurigo nodularis.The company reported fourth-quarter earnings per share of $11.86, which beat the Zacks Consensus Estimate of $10.43. The ye ...

ruizluquepazRegeneron (NASDAQ:REGN) has made significant progress since I initiated coverage in the summer of 2022 which was the time of the acquisition of Libtayo rights from partner Sanofi (SNY). I argued at the time that this was a great deal for Regeneron and shortly thereafter, that the company should return to growth after the revenue decline driven by the disappearance of COVID-19 revenues, and that the EV/revenue multiple should start to expand from below 5 to the 7-8 range and up to 10 during e ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2023 Earnings Conference Call February 2, 2024 8:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relations Leonard Schleifer - President and Chief Executive Officer George Yancopoulos - Co-Chair, Co-Founder, President and Chief Scientific Officer Marion McCourt - Executive Vice President and Head of Commercial Bob Landry - Executive Vice President and Chief Financial Officer Conference Call Participants Tyler Van Buren - TD Cowen Br ...

Regeneron (REGN) reported $3.43 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 0.6%. EPS of $11.86 for the same period compares to $12.56 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $3.26 billion, representing a surprise of +5.37%. The company delivered an EPS surprise of +13.71%, with the consensus EPS estimate being $10.43.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- an ...

Regeneron Corporate Presentation F E B R U A R Y 2 0 2 4 This non-promotional presentation contains investigational data as well as forward-looking statements; actual results may vary materially. Note regarding forward-looking statements and non-GAAP financial measures Thispresentationincludesforward-lookingstatementsthatinvolverisksanduncertaintiesrelatingtofutureeventsandthefutureperformanceofRegeneronPharmaceuticals,Inc.("Regeneron"orthe"Company"),andactual eventsorresultsmaydiffermateriallyfromtheseforw ...

Regeneron (REGN) came out with quarterly earnings of $11.86 per share, beating the Zacks Consensus Estimate of $10.43 per share. This compares to earnings of $12.56 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.71%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $10.80 per share when it actually produced earnings of $11.59, delivering a surprise of 7.31%.Over the last four quarte ...

Fourth quarter 2023 revenues increased 1% to $3.43 billion versus fourth quarter 2022; excluding RonapreveTM(a)(b), revenues increased 14%Full year 2023 revenues increased 8% to $13.12 billion versus full year 2022; excluding Ronapreve(a), revenues increased 12%Fourth quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 31% to $3.22 billion versus fourth quarter 2022; full year 2023 Dupixent global net sales increased 33% to $11.59 billion versus 2022Fourth quarter 2023 U.S. net sales for ...

TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for linvoseltamab to treat adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have progressed after at least three prior therapies. Linvoseltamab is an investigational bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells w ...

The upcoming report from Regeneron (REGN) is expected to reveal quarterly earnings of $10.48 per share, indicating a decline of 16.6% compared to the year-ago period. Analysts forecast revenues of $3.26 billion, representing a decrease of 4.7% year over year.The consensus EPS estimate for the quarter has undergone an upward revision of 0.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timefra ...